Ушбу ишга иқтибос қилган ишлар

2 та иш

Иш: Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

1. Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology

   Jinxin Dong, Denis Nikolenko, Shuxrat Boymuradov +2

   МақолаCAR-T cell therapy researchClinical & Translational Oncology20261 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.000172

2. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   МақолаCAR-T cell therapy researchJournal of Hematology & Oncology20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.article.000083